Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma
Frontiers in Pharmacology · 19.01.2024 · 14
DOI: 10.3389/fphar.2023.1336216 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 19.01.2024. Verfasst von Yumin Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, Ch…. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In light of a global rise in the number of patients with type 2 diabetes mellitus (T2DM) and obesity, non-alcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction-associated fatty liver disease (MAFLD) or metabolic dysfunction-associated steatotic liver disease (MASLD), has become the leading cause of hepatocellular carcinoma (HCC), with the annual occurrence of MASLD-driven HCC expected to increase by 45%–130% by 2030. Although MASLD has become a serious major public health threat globally, the exact molecular mechanisms mediating MASLD-driven HCC remain an open problem, necessitating future investigation. Meanwhile, emerging studies are focusing on the utility of bioactive compounds to halt the progression of MASLD to MASLD-driven HCC. In this review, we first briefly review the recent progress of the possible mechanisms of pathogenesis and progression for MASLD-driven HCC. We then discuss the application of bioactive compounds to mitigate MASLD-driven HCC through different modulatory mechanisms encompassing anti-inflammatory, lipid metabolic, and gut microbial pathways, providing valuable information for future treatment and prevention of MASLD-driven HCC. Nonetheless, clinical research exploring the effectiveness of herbal medicines in the treatment of MASLD-driven HCC is still warranted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China.
- Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, United States.
- Department of Traditional Chinese Medicine, Beijing Geriatric Hospital, Beijing, China.
- Department of Pharmacy, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China.
- Department of Peripheral Vascular Intervention, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China.
Zitieren
APA
Wang, Y., Fleishman, J. S., Li, T., Li, Y., Ren, Z., Chen, J., & Ding, M. (2024). Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1336216
Vancouver
Wang Y, Fleishman JS, Li T, Li Y, Ren Z, Chen J, et al. Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma. Frontiers in Pharmacology. 2024;14. doi:10.3389/fphar.2023.1336216
BibTeX
@article{Wang2024,
author = {Wang, Yumin and Fleishman, Joshua S and Li, Tongda and Li, Yulin and Ren, Zhao and Chen, Jichao and Ding, Mingchao},
title = {Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {14},
doi = {10.3389/fphar.2023.1336216}
}
EUVIMED